NASDAQ:SPRO Spero Therapeutics Q1 2025 Earnings Results & Report $1.00 -0.02 (-1.96%) Closing price 04:00 PM EasternExtended Trading$0.98 -0.02 (-1.80%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Spero Therapeutics beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.25 versus the -$0.55 consensus estimate, while revenue of $5.87 million fell short of the $11 million estimate by $5.13 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 13, 2025TimeBefore Market OpensConference Call4:00 PM ET Spero Therapeutics EPS ResultsActual EPS-$0.25Consensus EPS -$0.55Beat/MissBeat by +$0.30One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersSpero Therapeutics Revenue ResultsActual Revenue$5.87 millionExpected Revenue$11 millionBeat/MissMissed by -$5.13 millionYoY Revenue GrowthN/AUpcoming EarningsSpero Therapeutics' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Spero Therapeutics Q1 2025 Earnings FAQ Did Spero Therapeutics beat earnings estimates for Q1 2025? Spero Therapeutics (NASDAQ:SPRO) reported earnings of -$0.25 per share for Q1 2025, beating the consensus estimate of -$0.55. The report was announced on Tuesday, May 13, 2025. What was Spero Therapeutics' revenue for Q1 2025? Spero Therapeutics reported revenue of $5.87 million for Q1 2025, against a consensus estimate of $11 million. When is Spero Therapeutics' next earnings date? Spero Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Spero Therapeutics on the company's earnings history page. Spero Therapeutics Earnings HeadlinesSpero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business UpdateNovember 12 at 4:05 PM | globenewswire.comSpero Therapeutics, Inc. Announces Board and Committee ChangesNovember 11 at 9:40 PM | marketscreener.comMToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 12 at 1:00 AM | Behind the Markets (Ad)Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of DirectorsNovember 10 at 8:55 AM | finance.yahoo.comSpero Therapeutics (SPRO) Expected to Announce Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 4, 2026 | globenewswire.comSee More Spero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spero Therapeutics and other key companies, straight to your email. Email Address About Spero TherapeuticsSpero Therapeutics (NASDAQ:SPRO) (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections. The company has also advanced SPR720, an oral antibiotic candidate being studied for nontuberculous mycobacterial infections, and SPR206, an intravenous antibiotic candidate intended for serious infections caused by resistant Gram-negative bacteria. Founded in 2013 and headquartered in Cambridge, Massachusetts, Spero conducts its drug discovery and development activities primarily in the United States, with clinical and commercial development potentially involving international partners. The company has historically pursued collaborations and licensing arrangements to support the development and potential commercialization of its antibacterial programs.View Spero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
